Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01553539 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
A Phase 2 study of Recurrent Osteosarcoma and Chondrosarcoma, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT01553539: Completed Phase 2 study of Recurrent Osteosarcoma and Chondrosarcoma, sponsored by Wake Forest University Health Sciences.
NCT01553539 is a Phase 2 study of Recurrent Osteosarcoma and Chondrosarcoma that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants, below the 65-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01553539, a Phase 2 study of Recurrent Osteosarcoma and Chondrosarcoma, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery. Therapeutic angiotensin-(1-7) may stop the growth of sarcoma by blocking blood flow to the tumor. Funding Source - FDA Office of Orphan Drug Products (OOPD)
Primary Outcome
'Activity' will be operationalized using objective tumor response, which will be estimated as the proportion of partial and complete responders (according to Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) among all evaluable patients. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG therapeutic angiotensin-(1-7)
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT01553539 record still lists
NCT01553539 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 65-participant average among 13 other Recurrent Osteosarcoma trials with a reported enrollment target (69% lower).
The record links to 10 conditions, with Recurrent Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01553539 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01553539 about?
NCT01553539 is a clinical study titled "Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery". This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery. Therapeutic angiotensin-(1-7) may stop the growth of sarcoma by blocking blood flow to the tumor. Fun...
What is the current status of trial NCT01553539?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2009-10. Estimated completion is 2013-01.
What conditions does trial NCT01553539 study?
This clinical trial studies the following conditions: Recurrent Osteosarcoma, Chondrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Metastatic Osteosarcoma, Stage III Adult Soft Tissue Sarcoma.
What interventions are being tested in trial NCT01553539?
The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT01553539?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01553539 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Osteosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01553539's enrollment target sits among peer trials
20 13th of 13 higher than 1 of 13 other Recurrent Osteosarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Osteosarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
RECRUITING · Phase 2
-
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
ACTIVE NOT RECRUITING · Phase 2
-
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
COMPLETED · Phase 2
-
Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia